A promising target is not the same as a viable program. This session demonstrates how Quantitative Systems Pharmacology can be applied at the earliest stages of development to test whether a therapeutic concept warrants investment, covering indication selection, unmet need, mechanism prioritization, research target product profile development, and differentiation, and how these assessments contribute to a strategic roadmap toward First-in-Human.
Attendees will learn how to:
- Apply QSP-enabled feasibility assessment to evaluate indication selection, unmet need, and differentiation potential before committing significant investment.
- Prioritize compounds and mechanisms and shape research target product profiles using mechanistic modeling.
- Identify the knowledge gaps, critical experiments, and milestones needed to help de-risk a program ahead of clinical entry.
Speakers:
